MOTS-C vs SS-31

MOTS-C

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome, specifically within the 12S rRNA gene. Its primary mechanism of action involves activation of the AMPK pathway, which regulates cellular energy homeostasis by promoting glucose uptake and fatty acid oxidation independent of insulin signaling. Research published by Lee et al. (Cell Metabolism, 2015) demonstrated that MOTS-c use in diet-induced obese mice significantly improved glucose tolerance and reduced fat accumulation without altering food intake. Subsequent studies from the same USC laboratory showed that MOTS-c levels decline with age in human plasma, and that exercise increases circulating MOTS-c levels, suggesting it functions as a mitochondrial-derived exercise mimetic. Unlike traditional metabolic peptides that target specific membrane receptors, MOTS-c is unique in that it translocates to the nucleus under metabolic stress to regulate nuclear gene expression, particularly genes involved in the methionine-folate cycle and de novo purine biosynthesis. Compared to other mitochondrial-derived peptides like humanin, MOTS-c appears more specifically involved in metabolic regulation rather than cytoprotection. The lyophilized peptide should be stored at -20C and protected from light; reconstitute with bacteriostatic water and store reconstituted solutions at 2-8C for up to 21 days. MOTS-c is primarily researched by aging biology laboratories, exercise physiology departments, and mitochondrial medicine research centers investigating metabolic signaling peptides.

SS-31

SS-31, also known as Elamipretide or Bendavia (D-Arg-Dmt-Lys-Phe-NH2), is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Its primary mechanism involves binding to cardiolipin, a phospholipid unique to mitochondrial membranes that is essential for electron transport chain organization and ATP synthase function. By stabilizing cardiolipin microdomains, SS-31 modulates electron transfer between complexes III and IV, reduces electron leak, and limits reactive oxygen species (ROS) generation at the source. Research by Szeto (2006) published in AAPS Journal described SS-31's unique mitochondria-targeting pharmacology, demonstrating 5,000-fold concentration in mitochondria relative to cytoplasm within minutes of exposure. Clinical studies published in Circulation: Heart Failure by Daubert et al. showed that SS-31 improved left ventricular volumes in heart failure patients during a Phase 1/2 trial. Preclinical work in the Journal of the American Society of Nephrology demonstrated renal protective effects in ischemia-reperfusion injury models, with SS-31 preserving mitochondrial cristae structure and reducing tubular cell death. Compared to general antioxidants like CoQ10 or vitamin E, SS-31 targets ROS production at the mitochondrial source rather than scavenging free radicals after they are formed. This upstream approach is considered more efficient by researchers. MitoQ, another mitochondria-targeted compound, accumulates via membrane potential rather than cardiolipin binding, giving SS-31 a distinct pharmacological profile, particularly in depolarized or damaged mitochondria. Store lyophilized SS-31 at -20°C in a desiccated, light-protected environment. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. SS-31 is actively investigated by mitochondrial biologists, cardiologists studying heart failure, nephrologists, and aging researchers examining mitochondrial dysfunction as a driver of age-related disease.

Frequently Asked Questions